Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Nov;130(11):679-86.
doi: 10.1007/s00432-004-0596-1. Epub 2004 Aug 6.

Expression and clinical significance of CD44V5 and CD44V6 in resectable colorectal cancer

Francisco J Vizoso  1 , José C Fernández, María D Corte, Miguel Bongera, Richard Gava, María T Allende, José L García-Muñiz, Manuel García-Morán
Affiliations
Clinical Trial

Expression and clinical significance of CD44V5 and CD44V6 in resectable colorectal cancer

Francisco J Vizoso et al. J Cancer Res Clin Oncol. 2004 Nov.

Abstract

Purpose: This study was conducted to evaluate the prognostic significance of CD44v5 and CD44v6 in resectable colorectal cancer.

Materials and methods: Membranous CD44v5 and CD44v6 levels were measured by an immunoenzymatic assay in tumors and surrounding mucosal samples obtained from 105 patients with resectable colorectal carcinomas.

Results: There were no significant differences of CD44v5 levels between tumors [median: 3.2 (range: 0.9-83.5) ng/mg protein) and surrounding mucosal samples (3 (3-146.2) ng/mg protein]. However, tumor samples showed significantly higher CD44v6 levels [19.5 (2.2-562.9) ng/mg protein] than mucosal samples [5 (5-230) ng/mg protein] (P=0.0001). Patients with higher CD44v5 or CD44v6 content in tumor samples had a considerably shorter relapse-free survival (P<0.05, for both). Patients with a higher CD44v6 content also had a shorter relapse-free and overall survival in the multivariate analysis (P<0.05).

Conclusion: The results of this study suggest a role of CD44v5 and CD44v6 in colorectal cancer progression. Membranous CD44v levels in primary tumors, measured by immunoenzymatic assay, may contribute to a more precise prognostic estimation in patients with resectable colorectal cancer.

PubMed Disclaimer

Figures

Fig. 1A,B
Fig. 1A,B
Probability of A relapse free and B overall survival as a function of tumor CD44v5 levels in 105 patients with resectable colorectal carcinomas
Fig. 2A,B
Fig. 2A,B
Probability of A relapse free and B overall survival as a function of tumor CD44v6 levels in 105 patients with resectable colorectal carcinomas
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bates RC, Edwards NS, Burns GF, Fisher DE (2001) A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res 61:5275–5283 - PubMed
    1. Bhatavdekar JM, Patel DD, Chikhlikar PR, Trivedi TI, Gosalia NM, Ghosh N, Shah NG, Vora HH, Suthar TP (1998) Overexpression of CD44: a useful independent predictor of prognosis in patients with colorectal carcinomas. Ann Surg Oncol 5:495–501 - PubMed
    1. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254 - PubMed
    1. Broders A (1925) The grading of carcinoma. Minn Med 8:726
    1. Coppola D, Hyacinthe M, Fu L, Cantor AB, Karl R, Marcet J, Cooper DL, Nicosia SV, Cooper HS (1998) CD44V6 expression in human colorectal carcinoma. Hum Pathol 29:627–635 - PubMed

Publication types

MeSH terms